Rare Kidney Diseases Global Market Report 2024

Description

Rare kidney disease refers to a condition in which the kidneys do not function correctly, leading to the accumulation of waste in the body and causing health problems. This group of renal diseases has a low frequency in the general population and often has a genetic or hereditary origin.

The primary target indications for rare kidney diseases include IgA nephropathy, lupus nephritis, focal segmental glomerular sclerosis, membranous nephropathy, C3 glomerulopathy, and others. IgA nephropathy is a kidney disease characterized by the accumulation of antibodies (known as IgA) in kidney tissue, leading to inflammation. Treatment involves the use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) to lower blood pressure, reduce protein loss, slow the progression of kidney damage, manage symptoms, and prevent complications. The various types of molecules involved in treatment include small molecules and biologics, which are administered through various routes such as oral, intravenous, subcutaneous, and others.

The rare kidney diseases market research report is one of a series of new reports from The Business Research Company that provides Rare Kidney Diseases market statistics, including Rare Kidney Diseases industry global market size, regional shares, competitors with a Rare Kidney Diseases market share, detailed Rare Kidney Diseases market segments, market trends, and opportunities, and any further data you may need to thrive in the Rare Kidney Diseases industry. This Rare Kidney Diseases market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The rare kidney diseases market size has grown rapidly in recent years. It will grow from $2.52 billion in 2023 to $2.8 billion in 2024 at a compound annual growth rate (CAGR) of 11.0%. The increase observed in the historical period can be attributed to heightened disease recognition, designations of orphan drugs, increased patient advocacy and awareness, and global collaborations in research.

The rare kidney diseases market size is expected to see strong growth in the next few years. It will grow to $4.07 billion in 2028 at a compound annual growth rate (CAGR) of 9.8%. The anticipated growth in the forecast period can be attributed to the emergence of gene therapies, a rise in investment in rare disease research, increased collaboration between stakeholders, and global initiatives for rare diseases. Noteworthy trends expected during the forecast period include a patient-centric approach, the utilization of real-world evidence and data analytics, regulatory developments, the integration of telemedicine and remote monitoring, and the implementation of global health initiatives.

The anticipated growth of the rare kidney disease market is expected to be propelled by government initiatives and funding for kidney disorders. Government support, in the form of financial assistance, is directed towards entities with projects and ideas that contribute to improving public services and the economy. Specifically, in July 2022, The United States House Committee on Appropriations initiated various investment programs to promote kidney health, allocating $8.5 million for the Centers for Disease Control and Prevention's chronic kidney disease program. This funding aims to accelerate efforts in raising awareness, diagnosis, and treatment of kidney disease. Additionally, a $1 million investment was earmarked for the national living donor assistance center, totaling $8 million in ongoing investment in innovation and research. Thus, government initiatives and funding are key drivers of growth in the rare kidney disease market.

The significant increase in the prevalence of chronic kidney disease (CKD) is a substantial contributor to the growth of the rare kidney disease market. CKD, characterized by kidney damage and impaired blood filtering, elevates the risk of developing rare kidney diseases. According to the 2023 report from the Centers for Disease Control and Prevention (CDC), approximately 14% of US adults, around 35.5 million people, are estimated to have chronic kidney disease. This rise in CKD prevalence is expected to lead to an increased demand for therapeutics addressing rare kidney diseases, thereby driving the market's expansion.

Innovation in product development stands out as a prominent trend gaining traction in the rare kidney disease market. Major players in the market are strategically focusing on creating innovative products to fortify their market positions. For example, in September 2022, STADA Arzneimittel AG introduced Kinpeygo (budesonide), the first EU-authorized medicine for treating a rare kidney disease, specifically immunoglobulin A nephropathy (IgAN). This modified-release budesonide capsule represents a significant advancement in addressing the high unmet need in primary IgAN, a rare autoimmune kidney disease with a considerable impact on patients.

Companies operating in the rare kidney disease market are specifically emphasizing the development of non-immunosuppressive therapy. This unique treatment approach caters to patients with progressive kidney diseases, offering an alternative to traditional therapies for rare kidney diseases. For instance, in February 2023, Travere Therapeutics launched sparsentan, commercially known as Filspari, the first non-immunosuppressive therapy approved for primary immunoglobulin A nephropathy (IgAN). Filspari operates through a distinct mode of action by blocking angiotensin and endothelin receptors, setting it apart from conventional treatments such as ACE inhibitors and ARBs.

In February 2023, AstraZeneca Pharmaceuticals LP acquired CinCor Pharma Inc. for $1.8 billion. This acquisition positions AstraZeneca Pharmaceuticals LP to enhance its portfolio in chronic renal illness and uncontrolled hypertension, as CinCor Pharma Inc. brings valuable medications for rare kidney diseases to the company's offerings.

Major companies operating in the rare kidney diseases market report are Merck & Co. Inc., Novartis AG, Sanofi S.A, AstraZeneca PLC, GlaxoSmithKline PLC, Otsuka Pharmaceutical Co Ltd., Alexion Pharmaceuticals Inc., Horizon Therapeutics plc., Recordati S.p.A., Proteostasis Therapeutics, Amicus Therapeutics Inc., Akebia Therapeutics Inc., Travere Therapeutics, FibroGen Inc., Aurinia Pharmaceuticals Inc., Calliditas Therapeutics AB, Apellis Pharmaceuticals Inc., Protalix Biotherapeutics Inc., ChemoCentryx Inc., Omeros Corporation, Celtaxsys Inc., Corbus Pharmaceuticals Holdings Inc., Chinook Therapeutics Inc., Spyryx Biosciences Inc., OxThera AB, Advicenne Pharma SA, ProQR Therapeutics NV, Reata Pharmaceuticals Inc., Savara Inc.

North America was the leading region in the rare kidney disease market in 2023. The regions covered in the rare kidney diseases market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the rare kidney diseases market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The rare kidney disease market includes revenues earned by entities by providing services clinical evaluation, genetic counseling, genetic screening, specific testing, molecular diagnosis, hemodialysis, and peritoneal dialysis. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Rare Kidney Diseases Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on rare kidney diseases market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for rare kidney diseases ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The rare kidney diseases market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Target Indication: IgA Nephropathy; Lupus Nephritis; Focal Segmental Glomerular Sclerosis; Membranous Nephropathy; C3 Glomerulopathy; Other Target Indications
2) By Type of Molecule: Small Molecules; Biologics
3) By Route of administration: Oral; Intravenous; Subcutaneous; Other Routes of Administration
Companies Mentioned: Merck & Co. Inc.; Novartis AG; Sanofi S.A; AstraZeneca plc; GlaxoSmithKline plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r13832

1. Executive Summary

2. Rare Kidney Diseases Market Characteristics

3. Rare Kidney Diseases Market Trends And Strategies

4. Rare Kidney Diseases Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Rare Kidney Diseases Market Size and Growth

5.1. Global Rare Kidney Diseases Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Rare Kidney Diseases Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Rare Kidney Diseases Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Rare Kidney Diseases Market Segmentation

6.1. Global Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
IgA Nephropathy
Lupus Nephritis
Focal Segmental Glomerular Sclerosis
Membranous Nephropathy
C3 Glomerulopathy
Other Target Indications
6.2. Global Rare Kidney Diseases Market, Segmentation By Type of Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Small Molecules
Biologics
6.3. Global Rare Kidney Diseases Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Oral
Intravenous
Subcutaneous
Other Routes of Administration

7. Rare Kidney Diseases Market Regional And Country Analysis

7.1. Global Rare Kidney Diseases Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Rare Kidney Diseases Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Rare Kidney Diseases Market

8.1. Asia-Pacific Rare Kidney Diseases Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Rare Kidney Diseases Market, Segmentation By Type of Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Rare Kidney Diseases Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Rare Kidney Diseases Market

9.1. China Rare Kidney Diseases Market Overview
9.2. China Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Rare Kidney Diseases Market, Segmentation By Type of Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Rare Kidney Diseases Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Rare Kidney Diseases Market

10.1. India Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Rare Kidney Diseases Market, Segmentation By Type of Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Rare Kidney Diseases Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Rare Kidney Diseases Market

11.1. Japan Rare Kidney Diseases Market Overview
11.2. Japan Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Rare Kidney Diseases Market, Segmentation By Type of Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Rare Kidney Diseases Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Rare Kidney Diseases Market

12.1. Australia Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Rare Kidney Diseases Market, Segmentation By Type of Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Rare Kidney Diseases Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Rare Kidney Diseases Market

13.1. Indonesia Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Rare Kidney Diseases Market, Segmentation By Type of Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Rare Kidney Diseases Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Rare Kidney Diseases Market

14.1. South Korea Rare Kidney Diseases Market Overview
14.2. South Korea Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Rare Kidney Diseases Market, Segmentation By Type of Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Rare Kidney Diseases Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Rare Kidney Diseases Market

15.1. Western Europe Rare Kidney Diseases Market Overview
15.2. Western Europe Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Rare Kidney Diseases Market, Segmentation By Type of Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Rare Kidney Diseases Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Rare Kidney Diseases Market

16.1. UK Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Rare Kidney Diseases Market, Segmentation By Type of Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Rare Kidney Diseases Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Rare Kidney Diseases Market

17.1. Germany Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Rare Kidney Diseases Market, Segmentation By Type of Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Rare Kidney Diseases Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Rare Kidney Diseases Market

18.1. France Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Rare Kidney Diseases Market, Segmentation By Type of Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Rare Kidney Diseases Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Rare Kidney Diseases Market

19.1. Italy Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Rare Kidney Diseases Market, Segmentation By Type of Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Rare Kidney Diseases Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Rare Kidney Diseases Market

20.1. Spain Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Rare Kidney Diseases Market, Segmentation By Type of Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Rare Kidney Diseases Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Rare Kidney Diseases Market

21.1. Eastern Europe Rare Kidney Diseases Market Overview
21.2. Eastern Europe Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Rare Kidney Diseases Market, Segmentation By Type of Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Rare Kidney Diseases Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Rare Kidney Diseases Market

22.1. Russia Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Rare Kidney Diseases Market, Segmentation By Type of Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Rare Kidney Diseases Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Rare Kidney Diseases Market

23.1. North America Rare Kidney Diseases Market Overview
23.2. North America Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Rare Kidney Diseases Market, Segmentation By Type of Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Rare Kidney Diseases Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Rare Kidney Diseases Market

24.1. USA Rare Kidney Diseases Market Overview
24.2. USA Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Rare Kidney Diseases Market, Segmentation By Type of Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Rare Kidney Diseases Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Rare Kidney Diseases Market

25.1. Canada Rare Kidney Diseases Market Overview
25.2. Canada Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Rare Kidney Diseases Market, Segmentation By Type of Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Rare Kidney Diseases Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Rare Kidney Diseases Market

26.1. South America Rare Kidney Diseases Market Overview
26.2. South America Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Rare Kidney Diseases Market, Segmentation By Type of Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Rare Kidney Diseases Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Rare Kidney Diseases Market

27.1. Brazil Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Rare Kidney Diseases Market, Segmentation By Type of Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Rare Kidney Diseases Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Rare Kidney Diseases Market

28.1. Middle East Rare Kidney Diseases Market Overview
28.2. Middle East Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Rare Kidney Diseases Market, Segmentation By Type of Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Rare Kidney Diseases Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Rare Kidney Diseases Market

29.1. Africa Rare Kidney Diseases Market Overview
29.2. Africa Rare Kidney Diseases Market, Segmentation By Target Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Rare Kidney Diseases Market, Segmentation By Type of Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Rare Kidney Diseases Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Rare Kidney Diseases Market Competitive Landscape And Company Profiles

30.1. Rare Kidney Diseases Market Competitive Landscape
30.2. Rare Kidney Diseases Market Company Profiles
- 30.2.1. Merck & Co. Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Novartis AG
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Sanofi S.A
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. AstraZeneca plc
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. GlaxoSmithKline plc
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Rare Kidney Diseases Market Other Major And Innovative Companies

31.1. Otsuka Pharmaceutical Co Ltd.
31.2. Alexion Pharmaceuticals Inc.
31.3. Horizon Therapeutics plc.
31.4. Recordati S.p.A.
31.5. Proteostasis Therapeutics
31.6. Amicus Therapeutics Inc.
31.7. Akebia Therapeutics Inc.
31.8. Travere Therapeutics
31.9. FibroGen Inc.
31.10. Aurinia Pharmaceuticals Inc.
31.11. Calliditas Therapeutics AB
31.12. Apellis Pharmaceuticals Inc.
31.13. Protalix Biotherapeutics Inc.
31.14. ChemoCentryx Inc.
31.15. Omeros Corporation

32. Global Rare Kidney Diseases Market Competitive Benchmarking

33. Global Rare Kidney Diseases Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Rare Kidney Diseases Market

35. Rare Kidney Diseases Market Future Outlook and Potential Analysis

35.1 Rare Kidney Diseases Market In 2028 - Countries Offering Most New Opportunities
35.2 Rare Kidney Diseases Market In 2028 - Segments Offering Most New Opportunities
35.3 Rare Kidney Diseases Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer